Compare Consolidated Edison, Inc. (ED) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Novartis AG — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 6.9× Consolidated Edison, Inc.'s market cap, and Consolidated Edison, Inc. is more actively traded (2,142,900 versus 1,532,573). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Novartis AG for 82 Days on average.
| ED | NVS | |
|---|---|---|
Market Cap | $39.20B | $268.57B |
Volume | 2,142,900 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $115.46 | $168.62 |
52-Week Low | $95.37 | $121.80 |
Typical Hold Time | 75 Days | 82 Days |
Enterprise Value | $66.05B | $309.89B |
Dividend Yield | 3.31% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.10, up 1.39% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock's valuation appears reasonable with a P/E of 17.43 and P/S of 2.18, while profitability metrics like a 12.53% net income margin and 8.96% ROE reflect steady utility performance. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains strong cash flow from operations of $4.80 billion in 2025 and continues its dividend aristocrat status with a recent $0.89 dividend declaration.
ED offers stable income appeal with a solid dividend history, supported by regulated utility operations and a $24.8 billion economic impact in New York. However, high debt levels ($24.65 billion long-term) and modest growth prospects pose risks. Analyst sentiment is cautious with 62.96% hold ratings, though the consensus price target of $106.33 aligns with the current price, suggesting limited near-term upside amid economic sensitivity.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
